Friday, November 15, 2019

8:00-8:10 am  Welcome and Demographic Questions
Christopher G. Wood, Sr., M.D., FACS
Gretchen E. Vaughan
Lauren C. Harshman, M.D.

Current Understanding and Management of Rare Kidney Cancer Subtypes
Moderators: Sabina Signoretti, M.D.
Moshe Ornstein, M.D., MA

8:10-8:22 am  Updates in the WHO Kidney Cancer Classification Schemes
Michelle S. Hirsch, M.D., Ph.D.

8:22-8:32 am  Importance of Tumor Profiling for Rare Histology Variants
Ying-Bei Chen, M.D., Ph.D.

8:32-8:42 am  New Insights in Biology of Renal Medullary Cancer
Nizar M. Tannir, M.D., FACP

8:42-8:52 am  Insights into the Biology of Translocation-Associated (TFE3) Kidney Cancer
Eric C. Kauffman, M.D.

DEBATE: Optimal First Line Therapy for Rare Kidney Cancer Variants (Non-Clear Cell)

8:52-8:59 am  PRO-IO
Primo N. Lara, Jr. M.D.

8:59-9:06 am  PRO-Biologic Therapy
Matthew T. Campbell, M.D., MS

9:06-9:16 am  Abstract: Surgical Insights for Variant Histology
Gennady Bratslavsky, M.D.

9:16-9:23 am  Abstract: Identification of Oncocytic Neoplasms with Cyclin D1 Immunohistochemistry
Neil Mendhiratta, M.D., MS

9:23-9:30 am  Abstract: Effects of Immune Checkpoint Inhibitors on the Morphology of Renal Cell Carcinoma
Sasan Setoodeh, M.D.

9:30-9:40 am  Questions and Answers

9:40-9:55 am  Break
11:27-11:37 am Current Management Strategies for Immune Related Pneumonitis
Raja E. Abdulnour, M.D.

11:37-11:47 am Current Management Strategies for Immune Related Colitis
Yinghong Wang, M.D., Ph.D., MSc

11:47-11:57 am Current Management Strategies for Immune Related Neurologic Toxicity
Bianca D. Santomosso, M.D., Ph.D.

11:57-12:07 pm Current Management Strategies for Immune Related Cardiac Toxicity
Javid Moslehi, M.D.

12:07-12:12 pm Questions

12:12-1:22 pm A Combination Therapy for the First-Line Treatment of Advanced RCC

1:22-1:27 pm Introduction to the Eugene P. Schonfeld Memorial Lecture
Toni K. Choueiri, M.D.

1:27-2:07 pm Eugene P. Schonfeld Memorial Lecture
W. Kimryn Rathmell, M.D., Ph.D.

Keynote I
2:07-2:12 pm Introduction
Lisa Derosa, M.D., Ph.D.

2:12-2:32 pm Changing Paradigms in Statistical Interpretation—Do We Still Need the p Value?
Pavlos Msaouel, M.D., Ph.D.

2:32-2:37 pm Questions

2:37-2:42 pm Introduction
Michael A.S. Jewett, M.D., FRCSC

2:42-3:02 pm How Artificial Intelligence Can Improve Cancer Care
Mark Michalski, M.D.

3:02-3:07 pm Questions

Large Scale Research Efforts, Funding Initiatives and Advocacy
Moderators: Eric Jonasch, M.D.
E. Jason Abel, M.D., FACS

3:07-3:17 pm Overview of the UTSW SPORE
James Brugarolas, M.D., Ph.D.

3:17-3:27 pm Spotlight on Research From UTSW SPORE
Srinivas Malladi, Ph.D.

3:27-3:37 pm Overview of the Harvard SPORE
Toni K. Choueiri, M.D.

3:37-3:47 pm Spotlight on Research from Harvard SPORE
David A. Braun, M.D., Ph.D.

3:47-3:57 pm Advocating for Funding: An Advocates Perspective to Increasing Resources
Bryan Lewis

Deborah Maskens, MA, MSD

4:07-4:11 pm Questions

4:11-4:26 pm Break

DEBATE: Management of the Favorable Risk Patient with Metastatic RCC

4:28-4:38 pm PRO-Active Surveillance
Michael R. Harrison, M.D.

4:38-4:48 pm PRO-Monotherapy
Walter M. Stadler, M.D., FACP

4:48-4:58 pm PRO-Combination Therapy
André P. Fay, M.D., Ph.D.

4:58-5:08 pm Aiming to Personalize Immunotherapy with Existing and Emerging Biomarkers
Tian Zhang, M.D., MHS

5:08-5:18 pm Managing RCC in Challenging Immune Milieus
Elad Sharon, M.D., MPH
5:18-5:28 pm  Optimal Role of Consolidative Surgery in the IO Era
     Viraj Master, M.D., Ph.D., FACS
5:28-5:35 pm  Abstract: Incidence of Occult Brain Metastases Detected at Study Screening in Patients with Advanced Renal Cell Carcinoma
     Ritesh Kotecha, M.D.
5:35-5:42 pm  Abstract: Results from a Randomised Phase 1/2 Trial Evaluating the Safety and Anti-Tumor Activity of Anti-PD-1 (MEDI0680)/Anti-PD-L1 (Durvalumab) vs Anti-PD-1 (Nivolumab) Alone in Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)
     Martin H. Voss, M.D.
5:42-5:52 pm  Questions
6:00-8:00 pm  Reception and Posters in the Crystal Ballroom Terrace

Saturday, November 16, 2019
8:00-8:05 am  Welcome
     Brian M. Shuch, M.D.
8:05-8:15 am  CAIX Imaging
     Allan J. Pantuck, M.D.
8:15-8:25 am  Sestabimi Imaging
     Steve Rowe, M.D.
8:25-8:35 am  MRI- Clear Cell Score
     Ivan Pedrosa, M.D.
8:35-8:45 am  Metabolic Imaging
     Zhen J. Wang, M.D.
8:45-8:52 am  Abstract: Radiomic Signatures of CD8+ T Cell Infiltration and PD-L1 Expression in Clear-Cell Renal Cell Carcinoma (ccRCC)
     Haris Zahoor, M.D., MS
8:52-8:59 am  Abstract: An Exploratory Study of 89Zr-DFO Atezolizumab ImmunoPET/CT in Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
     Isaac A. Bowman, M.D.
8:59-9:09 am  Questions

Top Abstract Session
Moderators:  Bradley C. Leibovich, M.D., FACS
             Sandy Srinivas, M.D.
9:09-9:16 am  Circulating Tumor DNA (ctDNA) Results in 110 Patients with Advanced Renal Cell Carcinoma
     Ritesh Kotecha, M.D.
     Chirag Krishna, M.D.
9:23-9:30 am  Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1 Immune Checkpoint Inhibitor in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC): Results of an Interim Analysis
   Chung-Han Lee, M.D., Ph.D.

9:30-9:37 am  Treatment-Free Survival, With and Without Toxicity, as a Novel Outcome Applied to Immuno-Oncology Agents in Advanced Renal Cell Carcinoma
   Meredith M. Regan, Sc.D.

   Cristiane Bergerot, Ph.D.

9:42-9:49 am  Overall Survival from the Phase 3 TIVO-3 Study in Advanced Renal Cell Carcinoma
   Sumanta Kumar Pal, M.D.

9:49-9:59 am  Questions

Keynote II

9:59-10:23 am  Discovery of New IO Targets Leveraging CRISPR
   Arlene Sharpe, M.D., Ph.D.

10:23-10:33 am  Questions

10:33-11:45 am  CME Symposium
   How I Think, How I Treat: Understanding and Working With New Immunotherapeutic and Targeted Management Models in Advanced RCC
   Chair and Presenter: Toni K. Choueiri, M.D.
   Presenters: Hans J. Hammers, M.D., Ph.D.
   Rana McKay, M.D.

Emerging Kidney Cancer Targets
   Moderators: Charles G. Drake, M.D., Ph.D.
   Ari Hakimi, M.D.

11:45-11:57 am  T-Cell Differentiation and TCF
   Haydn T. Kissick, Ph.D.

11:57-12:09 pm  ERV
   Aguirre deCubas, Ph.D.

12:09-12:21 pm  MDSCs & Innate Cytokines
   Charles G. Drake, M.D., Ph.D.

12:21-12:33 pm  QSOX
   Thai H. Ho, M.D., Ph.D.

12:33-12:45 pm  Radiation to Prime the Immune System
   Hans J. Hammers, M.D., Ph.D.

12:45-12:57 pm  EZH2
   Leigh Ellis, Ph.D.

12:57-1:09 pm  Abstract: Prognostic Significance and Immune Correlates of CD73 Expression in Renal Cell Carcinoma (RCC)
   Abhishek Tripathi, M.D.

1:09-1:21 pm  Abstract: Loss of SETD2 is Associated with Dysregulation of Protein Translation in Clear Cell Renal Cell Carcinoma
   Scott M. Haake, M.D.

1:21-1:26 pm  Questions

"Wood Fire" Tumor Board
   Moderator: Christopher G. Wood, Sr., M.D., FACS

1:26-2:26 pm  Panelists
   M. Dror Michaelson, M.D., Ph.D.
   Ulka Vaishampayan, M.D.
   Robert A. Figlin, M.D., FACP
   Robert G. Uzzo, M.D., MBA, FACS
   Vitaly Margulis, M.D.
   Stephen A. Boorjian, M.D.

2:26-2:31 pm  Closing Comments
   Brian M. Shuch, M.D.
Eighteenth International Kidney Cancer Symposium

Thank you to our sponsors

**SILVER SPONSORS**

![EMD Serono](image1)

![Pfizer](image2)

**BRONZE SPONSORS**

![Bristol-Myers Squibb](image3)

![Exelixis](image4)

**EXHIBITORS**

![Eisai](image5)

![Merck](image6)

![Novartis](image7)

**SPONSOR**

![Aveo Oncology](image8)

Kidney Cancer Association
KidneyCancer.org